Digital Health Technology for People With Mitochondrial Disease

Launched by NEUROSCIENCE RESEARCH AUSTRALIA · Aug 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how digital health technology can help people with mitochondrial diseases (MD) improve their exercise habits. Many individuals with MD struggle to stay active, and finding experienced physiotherapists can be challenging, especially for those living in remote areas. This study aims to see if a structured home exercise program, supported by technology like smartwatches and online coaching, can make it easier for people with MD to stick to their exercise routines.

To participate, you need to be at least 18 years old, have a confirmed diagnosis of a mitochondrial disease, and be able to walk for at least 6 minutes. You should also have a smartphone and access to the internet. If you join the study, you will follow a personalized exercise plan for 8 weeks, receive weekly support through emails and video calls, and wear a smartwatch that reminds you to move. The researchers will check how well you do and ask about your feelings of fatigue and quality of life before and after the program. If successful, this approach could significantly help individuals with MD and may lead to better access to exercise support in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years of age
• • Have a confirmed diagnosis of a PMD
• • Be able to walk a minimum of 6 minutes with or without rest
• • Provide written informed consent and
• • Willingness and ability to comply with the study procedures
• • Own a smart phone and be willing to download 2 apps
• • internet access/telehealth app
• Exclusion Criteria:
• • Have atrial fibrillation or untreated symptomatic cardiac arrhythmia
• • Non-English speaking
• • Are pregnant
• • Are wheelchair bound
• • Have visual acuity less than 6/60 (Snellen Test)
• • Other co-morbidities such as severe osteoarthritis, balance impairment, chronic obstructive pulmonary disease, cognitive impairment, depression and anything else that would impact on participant adherence, participant safety or interpretation of results.